A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in ...

2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Introduction: Secondary genetic alterations, which contribute to the dysregulation of cell cycle progression and lymphoid specialization, are frequently observed in B-cell precursor acute ...

Background: Efficient classification of T-acute lymphoblastic leukemia (T-ALL) involves considering various factors, such as age, white blood cell count ... significantly differed from the diagonal ...

In this video, Marlise R. Luskin, MD, MSCE, discusses results from a phase 3 randomized trial that investigated the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute ...

Exactly what you can do varies. It depends on the treatment you have had and how fit you are. Life after a stem cell transplant for acute lymphoblastic leukaemia (ALL) It takes a long time to recover ...

Patients with myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem cell ... lymphocytic leukemia (CLL). Quality-of-life (QOL) outcomes vary widely for patients receiving first ...